[ad_1]
The Food and Drug Administration (FDA) has authorized the Food and Drug Administration (FDA) to acquire a state-of-the-art yellow fever vaccine production facility and is continuing the transition of YF-VAX production, to declared Sanofi Pasteur in a statement.
This is good news as Sanofi's yellow fever vaccine is a limited distribution vaccine distributed in the United States in 2019.
And the yellow fever virus can be fatal.
The Centers for Disease Control and Prevention (CDC) indicate that about 15% of people with yellow fever develop a serious illness that can be fatal.
"We are re-evaluating the return schedule for the YX-VAX vaccine and will provide an update by the end of 2019."
"Thus, the Expanded Access Program (EAP) for the STAMARIL vaccine in the United States will be maintained until the return of the YF-VAX vaccine," Sanofi said.
EAP authorizes import and use of STAMARIL vaccine in place of YF-VAX vaccine to meet yellow fever vaccination demand in the US until production resumes YF-VAX vaccine.
The STAMARIL vaccine is manufactured by Sanofi Pasteur in France. It is a live attenuated yellow fever vaccine that is being researched / unlicensed in the United States.
STAMARIL is however registered and distributed in more than 70 countries.
Latest news on the yellow fever virus:
Health care providers and patients can find places to administer STAMARIL vaccine by visiting this CDC webpage.
Providers and patients can also go here to find out which countries require yellow fever vaccination and for which countries the CDC recommends yellow fever vaccination.
The yellow fever virus is a mosquito-borne flavivirus that causes yellow fever, an acute infectious disease.
Vaccine counseling sessions prior to travel can be scheduled at Vax-Before-Travel.
Sanofi Pasteur continually strives to improve processes to maintain a constant supply of quality vaccines.
Relevant links: CDC vaccination schedules, CDC price list, vaccine adverse reaction reports, and international travel alerts.
Source link
